bpc-157 regulatory status fda not approved for human use BPC-157: The Real Reason Why It's FDA to discuss easing restrictions
Description
Korpeti et al., 2023) were published between 1981 and 2024 and comprised 13 randomised controlled trials, 2 case control study and 10 cohort studies (6 retrospective and 4 prospective)

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

These datasets have provided the foundation to model antibody structure, sequence diversity, and antibody-antigen interactions

In research, it is studied mainly for tissue repair, and it is known for acting locally at the site of injury rather than systemically
